REPORT HIGHLIGHT
The “Global Biosimilars Market- – Industry Analysis, Share, Trend, Market Size and Forecast” was estimated to be around US$ 11.69 billion in 2019 and is anticipated to grow with 26.9% of growth rate during the future period.

This report segments the global Biosimilars Market by product type, application and geography. Biosimilars are the biologics pharmaceutical drugs which are similar to the reference biologic products. These drugs are an interchangeable biological product that contains synthetically developed protein molecules. When the patent of branded drug is expired, pharmaceutical companies are planning to develop off-patent biologics i.e. biosimilars that offer similar biological activity. The biosimilars market offers many growth opportunities and driving factors as compared to the restraining factors. It is stated by various research scientists that development of biosimilars will drastically reduce the price of pharmaceutical drugs.

COVID-19's Multifaceted Impact on Biosimilars Industry
As the COVID-19 pandemic spreads, this will continue to affect the global biopharmaceutical industry. Biosimilars are no exception, and the impact on its demand and adoption will be multifaceted. The propose report discuss three possible forecast scenarios (probable, optimistic, and pessimistic) considering the COVID-19 impact. Our ongoing research analysis amplifies our framework to ensure the inclusion of underlying COVID-19 crisis impact and potential paths forward. The designed report is delivering detailed insights on COVID-19 considering the changes in consumer demand, purchasing patterns, re-routing of the supply chain, and the significant interventions of governments. The updated study provides insights, and forecast, considering the COVID-19 impact on the market.

In terms of product types, the market for recombinant glycosylated proteins continue to dominate during the forecast period, while the market for recombinant non-glycosylated proteins biosimilars will see a huge potential during the forecast period. On other side, oncology was the largest application segment in 2016, and expected to be the fastest growing application segment in the forecast period.

Companies reported in this report are: Amgen, Inc, AstraZeneca, Pfizer, Inc., BIOCON Limited, Novartis AG, STADA, Teva Pharmaceuticals Inc. and Others. For company profiles in the report, 2014 has been considered. Where information is unavailable for the base year, the prior year has been considered.

The market size and forecast for each segment has been provided for the period 2016 to 2027, considering 2019 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2021 to 2027 for every reported segment.

The years considered for the study are:

Historical Year – 2016 to 2018
Base Year – 2019
Estimated Year – 2020
Projected Year – 2027

The proposed reports analyse and evaluates the COVID-19 impact, and anticipated change on the future market scenario on this industry, by taking into the account the economic, political, technological, and social, parameters.

The research report categorizes the Biosimilars Market in each of the following submarkets to forecast the revenues and analyze the trends:

GLOBAL BIOSIMILARS MARKET, BY PRODUCT TYPES
Recombinant Glycosylated Proteins
Recombinant Non-Glycosylated Proteins
Recombinant Peptides

GLOBAL BIOSIMILARS MARKET, BY APPLICATION
Oncology
Blood Disorders
Infectious Diseases
Autoimmune Diseases
Others

GLOBAL BIOSIMILARS MARKET, BY REGION
North America
Europe
Asia Pacific
Rest of the World